-
April 19, 2024Elpiscience will be hosting International Symposium on Cell Engagers and Cancer Immunotherapy
We are proud to announce that Elpiscience will be hosting the prestigious International Symposium on Cell Engagers and Cancer Immunotherapy in Crowne Plaza, Suzhou, China on June 28-29, 2024.&nbs...
-
April 12, 2024Elpiscience Announces the Appointment of Jason John Luke, M.D., to its Scientific Advisory Board
Shanghai, Suzhou, China April 3,2024 Elpiscience Biopharmaceuticals announces the Appointment of Jason Luke M.D., to its Scientific Advisory Board. “We are excited to have Dr. Luke ...
-
December 28, 2023Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. today announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program.
-
November 06, 2023Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Elpiscience Biopharmaceuticals presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting. Check out the highlights.
-
October 24, 2023Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Elpiscience Biopharmaceuticals today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego.
-
September 26, 2023Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia
Elpiscience Biopharmaceuticals announced that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.
